Cited by
Cited by
Computational oncology—mathematical modelling of drug regimens for precision medicine
D Barbolosi, J Ciccolini, B Lacarelle, F Barlési, N André
Nature reviews Clinical oncology 13 (4), 242-254, 2016
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients
C Solas, A Lafeuillade, P Halfon, S Chadapaud, G Hittinger, B Lacarelle
Antimicrobial agents and chemotherapy 47 (1), 238-243, 2003
Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients.
J Albanese, C Martin, B Lacarelle, P Saux, A Durand, F Gouin
Anesthesiology 73 (2), 214-217, 1990
Pharmacogenetics of capecitabine in advanced breast cancer patients
R Largillier, MC Etienne-Grimaldi, JL Formento, J Ciccolini, JF Nebbia, ...
Clinical cancer research 12 (18), 5496-5502, 2006
First results on ProtoDUNE-SP liquid argon time projection chamber performance from a beam test at the CERN Neutrino Platform
B Abi, AA Abud, R Acciarri, MA Acero, G Adamov, M Adamowski, ...
Journal of instrumentation 15 (12), P12004, 2020
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy
J Ciccolini, C Mercier, A Evrard, L Dahan, JC Boyer, F Duffaud, K Richard, ...
Therapeutic drug monitoring 28 (5), 678-685, 2006
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil–related severe toxicities: hype or hope?
J Ciccolini, E Gross, L Dahan, B Lacarelle, C Mercier
Clinical colorectal cancer 9 (4), 224-228, 2010
A simple and rapid high‐performance liquid chromatographic (HPLC) method for 5‐fluorouracil (5‐FU) assay in plasma and possible detection of patients with impaired …
J Ciccolini, C Mercier, MF Blachon, R Favre, A Durand, B Lacarelle
Journal of clinical pharmacy and therapeutics 29 (4), 307-315, 2004
Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations
A Lafeuillade, C Solas, P Halfon, S Chadapaud, G Hittinger, B Lacarelle
HIV clinical trials 3 (1), 27-35, 2002
Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites
E Seree, PH Villard, JM Pascussi, T Pineau, P Maurel, QB Nguyen, ...
Gastroenterology 127 (5), 1436-1445, 2004
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
CG Yang, J Ciccolini, A Blesius, L Dahan, D Bagarry-Liegey, C Brunet, ...
Cancer chemotherapy and pharmacology 67, 49-56, 2011
Thawed human hepatocytes in primary culture
M Dou, G De Sousa, B Lacarelle, M Placidi, PL de La Porte, M Domingo, ...
Cryobiology 29 (4), 454-469, 1992
Effects of Tobacco Smoke on the Gene Expression of theCyp1a, Cyp2b, Cyp2e, andCyp3aSubfamilies in Mouse Liver and Lung: Relation to Single Strand Breaks of DNA
PH Villard, EM Seree, JL Re, M De Meo, Y Barra, L Attolini, G Dumenil, ...
Toxicology and applied pharmacology 148 (2), 195-204, 1998
Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs
C Le Guellec, B Lacarelle, PH Villard, H Point, J Catalin, A Durand
Anesthesia & Analgesia 81 (4), 855-861, 1995
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine
S Benzekry, E Pasquier, D Barbolosi, B Lacarelle, F Barlési, N André, ...
Seminars in Cancer Biology 35, 53-61, 2015
Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration
I Poizot-Martin, C Solas, J Allemand, V Obry-Roguet, V Pradel, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (4), 375-380, 2013
Effect of cigarette smoke on UDP‐glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice
PH Villard, R Hcrber, EM Sérée, L Attolini, J Magdalou, B Lacarelle
Pharmacology & toxicology 82 (2), 74-79, 1998
Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A
M Gantenbein, L Attolini, B Bruguerolle, PH Villard, F Puyoou, A Durand, ...
Drug metabolism and disposition 28 (4), 383-385, 2000
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
R Grepin, M Guyot, M Jacquin, J Durivault, E Chamorey, A Sudaka, ...
Oncogene 31 (13), 1683-1694, 2012
Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
TF Woolf, WF Pool, SM Bjorge, T Chang, OP Goel, CF Purchase, ...
Drug metabolism and disposition 21 (5), 874-882, 1993
The system can't perform the operation now. Try again later.
Articles 1–20